Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2017-04-25 | Mr. Swirsky has served as President and Chief Executive Officer of GenVec, Inc., a clinical-stage biopharmaceutical company, since 2013, and also serves as a member of GenVec's board of directors. From 2006 through 2014, Mr. Swirsky served as Senior Vice President, Chief Financial Officer, Treasurer and Corporate Secretary of GenVec. Prior to joining GenVec in September 2006, Mr. Swirsky worked at Stifel Nicolaus where he served as a Managing Director and the Head of Life Sciences Investment Banking. Mr. Swirsky previously held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason. His experience also includes positions in public accounting and consulting. |
| 2018-04-23 | Mr. Swirsky received his undergraduate degree in business administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. |
| 2019-04-29 | Mr. Swirsky received his undergraduate degree in business administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a Certified Public Accountant and a CFA® charterholder. Mr. Swirsky is a member of the board of directors of Fibrocell Science, Inc. and Pernix Therapeutics Holdings, Inc. Within the past five years, Mr. Swirsky has also served on the board GenVec, Inc. Our Board concluded that Mr. Swirsky should serve as a director and member of Compensation Committee along with Nominating and Corporate Governance Committee because of his distinguished career in financial services and corporate management, including his investment banking experience and his experience serving as a principal executive officer and principal financial officer. |
| 2020-04-28 | Mr. Swirsky has a distinguished career in financial services and corporate management, including his investment banking experience and his experience serving as a principal executive officer and principal financial officer. |
| 2021-05-13 | Mr. Swirsky has served as CFO and CEO of biopharmaceutical companies and holds an undergraduate degree in business administration and an MBA. He is a Certified Public Accountant and CFA charterholder. |
| 2022-04-29 | Mr. Swirsky previously held investment banking positions at Stifel, UBS, PaineWebber, Morgan Stanley, and Legg Mason. His experience also includes positions in public accounting and consulting. Mr. Swirsky received his undergraduate degree in business administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a Certified Public Accountant and a CFA® charterholder. |
| 2023-04-28 | Mr. Swirsky has served as Chief Financial Officer of MaxCyte, Inc., a publicly traded biotechnology company... Mr. Swirsky received his undergraduate degree in business administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. |
| 2024-04-26 | Mr. Swirsky received his undergraduate degree in business administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a Certified Public Accountant and a CFA charterholder. |
| Filing Date | Source Excerpt |
|---|---|
| 2018-07-23 | Douglas J. Swirsky No stock ownership but mentioned as an executive officer and proxy appointee. |
| 2019-02-14 | Douglas J. Swirsky - President and Chief Executive Officer |
| 2019-04-29 | Mr. Swirsky is a certified public accountant and a CFA® charter holder. He received his B.S. in Business Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22